ANKHD1 Knockout A-549 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A-549 lung epithelial carcinoma line. Gene disruption is achieved through CRISPR/Cas9-mediated targeting, yielding a heterogeneous pool of edited cells that provide a robust loss-of-function model. The polyclonal nature preserves genetic diversity, minimizing clone-specific artifacts and supporting generalizable findings. Supplied as viable, proliferating cells, this product is optimized for downstream functional assays.
The host cell line A-549, established from a lung adenocarcinoma of a 58-year-old male, serves as a widely used model of alveolar Type II epithelium and lung adenocarcinoma. Its extensive characterization in respiratory and cancer research makes it an ideal background for studying genes implicated in oncogenic signaling.
ANKHD1 encodes a scaffold protein containing ankyrin repeats and a KH domain, acting as a critical modulator of JAK-STAT signaling. It interacts directly with JAK2 kinase and SHP2 phosphatase (PTPN11) to regulate STAT5 transcriptional activity downstream of cytokine receptors such as GM-CSFR and IL-3R. Cytokines like GM-CSF and IL-3 trigger JAK2 activation, and ANKHD1 scaffolds these interactions to fine-tune proliferative and survival signals. Disruption of ANKHD1 impairs this network, altering cell cycle regulation and apoptotic responses. Consequently, knockout cells may exhibit altered STAT5 phosphorylation and dysregulation of cell cycle and apoptosis regulators.
In A-549 cells, ANKHD1 knockout provides a relevant model for investigating JAK-STAT pathway contributions to lung adenocarcinoma progression and therapeutic response. Although initially characterized in hematopoietic malignancies, ANKHD1’s scaffold function may influence solid tumor biology, and this system enables tissue-context studies of signaling dependencies. Moreover, this model facilitates testing of JAK2 or STAT5 inhibitors, aiding in identification of synthetic lethal interactions or resistance mechanisms in lung cancer.
Typical applications include functional characterization via western blotting and RT-qPCR, cell proliferation (MTT/CCK-8) and apoptosis (annexin V) assays, colony formation analysis to assess tumorigenic potential, phospho-STAT5 flow cytometry for pathway activity, and transcriptomic profiling by RNA-seq. Drug sensitivity tests with kinase inhibitors further expand utility, particularly for evaluating targeted therapy responses. For additional information, including lot-specific data, please contact Ascent Research.
